Georges Niang (Utah Jazz) with a dunk vs the New Orleans Pelicans, 01/19/2021
Georges Niang (Utah Jazz) with a dunk vs the New Orleans Pelicans, 01/19/2021
NASHVILLE — A person familiar with the deal says the Tennessee Titans have traded offensive lineman Isaiah Wilson to the Miami Dolphins in a move unloading their first-round draft pick after his rookie season. The trade agreed to Monday night sends the 29th overall pick in 2020 out of Georgia to Miami after Wilson played only four snaps as a rookie, according to the person who spoke on condition of anonymity because neither team had announced the swap. NFL.com first reported the trade, saying a swap of picks also is involved. This deal caps a tenure in Tennessee that was filled with turmoil on and off the field for Wilson. The Titans suspended Wilson for a game, then placed him on injured reserve/non-football illness list on Dec. 9 to deal with what general manager Jon Robinson called “personal issues.” The Titans needed Wilson with three-time Pro Bowl left tackle Taylor Lewan tearing his right ACL and his replacement also wound up on injured reserve. Robinson said Feb. 16 that he hadn't spoken to Wilson since the tackle was placed on IR. ___ More AP NFL coverage: https://apnews.com/hub/NFL and https://twitter.com/AP_NFL Teresa M. Walker, The Associated Press
An altered image appears to show Texas Gov. Greg Abbott tweeting that he intentionally endangered Texans. His office confirmed the tweet is fake.
The former first round pick played just four snaps all year, and tweeted he was "done with" Tennessee last month.
DC Comics fans just got an unexpected surprise… from the unlikeliest of places. Zach Snyder’s long-awaited director’s cut of Justice League, aka the #SnyderCut, is due to hit HBO Max next week, but it accidentally leaked on the streamer early on Monday, with multiple users reporting that when they tried to press play on the […]
The HSBC Women's World Championship golf tournament will return to Singapore's Sentosa Golf Club from 29 April to 2 May.
TSX Trading symbol: UTORONTO, March 8, 2021 /CNW/ - Uranium Participation Corporation ("UPC") (TSX: U) reports its estimated net asset value at February 28, 2021 was CAD$623. As at February 28, 2021, UPC's uranium investment portfolio consisted of the following:(in thousands of Canadian dollars, except quantity amounts) QuantityFair Value Investments in Uranium: Uranium oxide in concentrates ("U3O8") 16,269,658 lbs$581,993 Uranium hexafluoride ("UF6") 300,000 KgU$35,772 $617,765 U3O8 fair value1 per pound: \- In Canadian dollars1 $35.
WME has signed documentary filmmaker Kareem Tabsch, best known for co-directing the Netflix documentary, Mucho Mucho Amor, about the life of Walter Mercado. The docu, which premiered at the 2020 Sundance Film Festival, tells the story of the beloved cultural icon and astrologer who delivered daily horoscopes on television to avid fans in his native […]
An employee of Virginia's government watchdog agency filed a lawsuit Monday seeking whistleblower status and alleging she faced retaliation after coming forward with details of perceived wrongdoing arising from an investigation of the state parole board. Jennifer Moschetti, an investigator with the Office of the State Inspector General who was tasked with looking into complaints about the board, says in her lawsuit that she was put on “pre-disciplinary leave” Friday. The lawsuit alleges the move came days after she sought to come forward to state lawmakers as a whistleblower by providing documents related to her work on the investigation.
As part of the deal, four-year old Global Companies Fund with more than $500 million of assets under management would be transferred to Fiera Capital. AMP Capital's four-person investment team would also move to Fiera Capital, AMP said.
Deadline has made a pair of staff moves as it continues its editorial expansion. London-based reporter Diana Lodderhose is returning to the site’s fold as International Features Editor, while Alexandra Del Rosario, currently Associate Editor, Nights & Weekends, has shifted to TV Reporter. “We are thrilled to have Diana back at Deadline and excited about […]
Glancy Prongay & Murray LLP ("GPM"), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Suh v. XL Fleet Corp., et al., (Case No. 1:21-cv-02002) on behalf of persons and entities that purchased or otherwise acquired XL Fleet Corp. ("XL Fleet" or the "Company") (NYSE: XL) securities between October 2, 2020 and March 2, 2021, inclusive (the "Class Period"). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act").
"It's complicated! It requires a lot of multitasking," Katie Couric tells PEOPLE of guest-hosting the game show
Kelowna, BC, March 08, 2021 (GLOBE NEWSWIRE) -- GTEC Holdings Ltd. (TSXV:GTEC) (OTCQB: GGTTF) (FRA: 1BUP) (“GTEC”, the “Company” or “GTEC Cannabis Co.”) a multi-licensed producer of handcrafted, high quality cannabis, is pleased to announce the signing of an export deal pertaining to the Israeli medical cannabis market (the “Agreement”). Executes multi-year agreement to export a minimum of 500 KG annually to Israel, one of the world’s largest import markets for medical cannabisAgreement enables GTEC to enter into global distribution of its handcrafted ultra-premium flowerExport deal demonstrates the demand for GTEC products within Canada and globally The Company has entered into an agreement with Focus Medical Herbs Ltd. ("Focus Medical"), an Israeli medical cannabis company with which IM Cannabis Corp. (“IMC”) (NASDAQ: IMCC) has exclusive distribution agreements to export cannabis from Canada to Israel, subject to meeting all regulatory requirements both in Israel and Canada. Under the terms of this agreement, GTEC is expected to become a key supplier of cannabis to Focus Medical. The Company’s initial shipments of cannabis will be produced by its wholly-owned subsidiary, Grey Bruce Farms (“GBF”), located in Tiverton, Ontario, with the expectation that GTEC will export 500 to 1,000 KG per year.Michael Blady, Co-founder and VP of GTEC commented, "We are very excited to sign this agreement adding our ultra-premium product to the well-known IMC brand in Israel, this demonstrates the robust demand for GTEC products within Canada and globally. With the signing of this deal, GTEC will become an up-and-coming player within the global cannabis market, while continuing to drive significant incremental revenues and gross margin.”“Medical cannabis patients in Israel are starting to demand more imported indoor products from Canada. By partnering with GTEC to supply high-THC flower from its Canadian indoor facility, IMC is leveraging this increasing demand from patients and will, for the first time, bring into Israel a truly ultra-premium quality product. We are thrilled about the launch of this new category and expect to grow its market share domestically,” Oren Shuster, Chief Executive Officer of IMC commented.In order to qualify as a supplier to the Israeli medical cannabis market, GBF successfully completed a rigorous audit process conducted by The Institute of Quality & Control (“IQC), the largest private certification body in Israel. This comprehensive audit process covered all aspects of the GBF operations, including cultivation, quality assurance and human resources. As a result, GBF has received its ICANN-G.A.P (Good Agricultural Practices) accreditation from IQC.The Company considers the Agreement to reinforce GTEC's competitive advantage in the production of ultra-premium cannabis. Currently there are more than 320 Standard Cultivation Licences issued by Health Canada, and being selected as Focus Medical's key supplier demonstrates the quality and demand of GTEC's products. The Company will continue to evaluate opportunities within the global cannabis market, with the objective to further expand its global distribution channels.About IM Cannabis Corp.IMC is a multi-country operator (MCO) in the medical cannabis sector headquartered in Israel and with operations In Israel and Germany. Over the past decade, the IMC brand has become synonymous with quality and consistency in the Israeli medical cannabis market. IMC has also expanded its business to offer intellectual property-related services to the medical cannabis industry.In Europe, IMC operates through Adjupharm, a German-based subsidiary and EU-GMP certified medical cannabis distributor. IMC’s European presence is augmented by strategic alliances with various pan-European EU-GMP cultivators and distributors to capitalize on the increased demand for medical cannabis products in Europe and bring the IMC brand and its product portfolio to European patients.About Focus Medical Herbs Ltd. Focus Medical is one of eight original licensed producers of medical cannabis in Israel and has over 10 years of experience growing high-quality medical cannabis in the Israeli market. Focus Medical is an “investee” of IMC under IFRS due to the IMC’s “de facto control” over Focus Medical, despite not having any direct or indirect ownership of it. Focus Medical has an exclusive commercial agreement with IMC to distribute its production under the IMC brand. In addition to its own capacity, Focus Medical has signed supply agreements with other cultivators for additional supply using its proprietary genetics and for sale under the IMC brand.For parties interested in global export opportunities, please contact:Michael Blady - Co-Founder and Vice President email@example.comNon-Brokered Private PlacementThe Company is also pleased to announce that it has completed its previously announced non-brokered private placement (the “Offering”) of 13,750,000 units (each, a “Unit”) at a price $0.20 per Unit for gross proceeds of $2,750,000. Each “Unit” issued in the placement consists of one common share and one half of one share purchase warrant entitling the holder to purchase one additional share at $0.30 for a period of three years from closing of the Offering.The Company filed for price reservation based on the closing price per common share of $0.245 on February 5, 2021 (which was the 52-week high for the Common Shares as of February 5, 2021). Commitments to subscribe in the Offering that were received on or before the close of markets on February 9, 2021, totaled $2.75 million. Further commitments were later received with demand significantly exceeding the $4 million, however as a result of the increase in the Company’s share price, the Company elected to close the book and not accept any further commitments. All securities issued pursuant to the Offering are subject to a statutory hold period lasting four months and one day following the closing of the Offering.About GTEC Cannabis CoGTEC Cannabis Co. cultivates, markets and distributes premium cannabis products. The Company has four operational facilities licensed by Health Canada and currently distributes cannabis through medical and recreational sales channels. GTEC’s recreational product portfolio is crafted from unique cultivars and marketed under its BLK MKT™ , Tenzo™, Cognōscente™ and Treehugger™ brands. The Company’s medical cannabis brand, GreenTec™, is distributed nationally to qualified patients through its through its GreenTec Medical web-site and various licensed partners.GTEC is a publicly traded corporation, listed on the TSX Venture Exchange (GTEC), OTCQB Venture Market (GGTTF) and Frankfurt Stock Exchange (1BUP). The Company’s headquarters is located in Kelowna, B.C. and it has operations in the Canadian provinces of British Columbia, Alberta and Ontario.To learn more about the Company or to access the most recent Corporate Presentation, please visit our website at www.gtec.coNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:This news release includes certain “forward-looking statements” and “forward-looking information” under applicable Canadian securities legislation (collectively, “forward -looking statements”). Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as “intend,” “goal,” “strategy,” “estimate,” “expect,” “project,” “projections,” “forecasts,” “plans,” “seeks,” “anticipates,” “potential,” “proposed,” “will,” “should,” “could,” “would,” “may,” “likely,” “designed to,” “foreseeable future,” “believe,” “scheduled” and other similar expressions. The forward-looking statements contained herein may include, but are not limited to, GTEC becoming a key supplier of cannabis to Focus Medical, the expectation that GTEC will export 500 to 1,000 KG of cannabis per year to Focus Medical, GTEC becoming an up-and-coming player within the global cannabis market, while continuing to drive significant incremental revenues and gross margin, and the Agreement reinforcing GTEC's competitive advantage in the production of ultra-premium cannabis. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals, where applicable and the state of the capital markets. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. For instance and among other things, there are risks that the COVID-19 pandemic may disrupt the Company’s operations, those of the Company’s suppliers and distribution channels and negatively impact the use of the Company’s products, the Company may not be able to successfully ship to Israel and generate positive gross margins; issues compliance with applicable environmental, economic, health and safety, energy and other policies and regulations with respect to the use of cannabis; actions of third parties such as competitors, activist investors or federal, provincial, territorial or local regulatory authorities, self-regulatory organizations, plaintiffs in litigation or persons threatening litigation; changes in regulatory requirements in relation to the Company’s business and products. Accordingly, readers should not place undue reliance on forward-looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. CONTACT: For additional information, please contact: GTEC Cannabis Co. 1-800-351-6358 firstname.lastname@example.org
The retailer is running low on dog and cat food pouches and says the issue will be "ongoing" in 2021.
New York, New York--(Newsfile Corp. - March 8, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Walmart Inc. (NYSE: WMT) between March 30, 2016 and December 22, 2020, inclusive (the "Class Period"), of the important March 22, 2021 lead plaintiff deadline in the securities class action first filed by the firm.SO WHAT: If you purchased Walmart securities during the Class Period you may ...
VANCOUVER, BC, March 8, 2021 /CNW/ - TSX VENTURE COMPANIESNICKEL 28 CAPITAL CORP. ("NKL") [formerly, Conic Metals Corp.
‘They don’t get to leave. And I have huge compassion for that’
Toyota may have pioneered the just-in-time manufacturing strategy but when it comes to chips, its decision to stockpile what have become key components in cars goes back a decade to the Fukushima disaster. After the catastrophe severed Toyota's supply chains on March 11, 2011, the world's biggest automaker realised the lead-time for semiconductors was way too long to cope with devastating shocks such as natural disasters. That's why Toyota came up with a business continuity plan (BCP) that required suppliers to stockpile anywhere from two to six months' worth of chips for the Japanese carmaker, depending on the time it takes from order to delivery, four sources said.
CALGARY — Alberta's top court has ordered a third trial for a couple who said they thought their toddler son had croup and were treating him with natural remedies before he died. David and Collet Stephan were accused of not seeking medical attention sooner for 19-month-old Ezekiel, who died in 2012. A jury convicted them in 2016, but the Supreme Court of Canada overturned that verdict and ordered a second trial. A judge hearing the case without a jury found then not guilty in 2019. The Alberta Court of Appeal on Monday granted a request by the Crown to overturn the acquittal. David Stephan responded to the decision in a text to The Canadian Press. "Once again the Alberta Court of Appeals has showcased its gross level of corruption," he wrote. The Alberta Crown Prosecution Service did not say when a new trial might be held. "It is the duty and obligation of every prosecutor to continually assess all files to ensure they meet the prosecution standard, reasonable likelihood of conviction and public interest," said a statement. Over the course of their trials, the Stephans testified that they initially thought Ezekiel had croup, an upper airway infection, and treated him with natural remedies, including a smoothie with tinctures of garlic, onion and horseradish. They said he appeared to be recovering at times and they saw no reason to take him to hospital, despite his having a fever and lacking energy. They called an ambulance when the boy stopped breathing. In acquitting them at their second trial, Justice Terry Clackson accepted the testimony of a defence expert, who said the boy died of a lack of oxygen, not bacterial meningitis as reported by Dr. Bamidele Adeagbo, the original medical examiner in the case. Clackson noted in his decision that Adeagbo, who was born in Nigeria, spoke with an accent and was difficult to understand. "His ability to articulate his thoughts in an understandable fashion was severely compromised by: his garbled enunciation; his failure to use appropriate endings for plurals and past tenses; his failure to use the appropriate definite and indefinite articles; his repeated emphasis of the wrong syllables; dropping his Hs; mispronouncing his vowels; and the speed of his responses,'' Clackson wrote. The judge also called out Adeagbo for "body language and physical antics ... not the behaviours usually associated with a rational, impartial professional imparting opinion evidence.'' The Appeal Court judges ruled that the judge's critical comments about Adeagbo demonstrated the need for a new trial and for the not guilty verdicts against the Stephans to be set aside. "It is inappropriate to disparage witnesses for their pattern of speech, accents or less than perfect command of one of Canada’s official languages. Or of any language for that matter," wrote Chief Justice Catherine Fraser. "No witness should fear their testimony will be dismissed or discredited because of their manner of speech." Fraser said Clackson's comments about Adeagbo were irrelevant to issues of evidence admissibility and suggest the judge rejected the medical examiner's evidence based "on the form it took, including the doctor's manner of speech, not its substance." "We have concluded that an informed person would view the trial judge's conduct as giving rise to a reasonable apprehension of bias," Fraser wrote. "In these circumstances, a new trial is the only available remedy." The appellant judges also noted that Clackson erred by requiring the Crown to prove whether timely medical treatment would have saved Ezekiel's life, although they said that oversight wouldn't have been enough on its own to require a new trial. After Clackson's verdict, dozens of medical and legal experts filed a complaint against him with the Canadian Judicial Council alleging the comments he made about Adeagbo could be perceived as racist. This report by The Canadian Press was first published March 8, 2021. — Follow @BillGraveland on Twitter Bill Graveland, The Canadian Press
Leading airline and business groups are asking the Biden administration to develop temporary credentials that would let travelers show they have been tested and vaccinated for COVID-19, a step that the airline industry believes will help revive travel. Various groups and countries are working on developing so-called vaccine passports aimed at allowing more travel. “It is crucial to establish uniform guidance" and “the U.S. must be a leader in this development,” more than two dozen groups said in a letter Monday to White House coronavirus-response coordinator Jeff Zients.